Cost-Effectiveness of Lower Extremity Nerve Decompression Surgery in the Prevention of Ulcers and Amputations: A Markov Analysis

Cost-effectiveness of temperature monitoring to help prevent foot ulcer recurrence in people with diabetes: A multicenter randomized controlled trial

AIMS

Diabetes-related foot ulcers are common, costly, and frequently recur. Multiple interventions help prevent these ulcers. However, none of these have been prospectively investigated for cost-effectiveness. Our aim was to evaluate the cost-effectiveness of at-home skin temperature monitoring to help prevent diabetes-related foot ulcer recurrence.

MATERIALS AND METHODS

Multicenter randomized controlled trial. We randomized 304 persons at high diabetes-related foot ulcer risk to either usual foot care plus daily at-home foot skin temperature monitoring (intervention) or usual care alone (control). Primary outcome was cost-effectiveness based on foot care costs and quality-adjusted life years (QALY) during 18 months follow-up. Foot care costs included costs for ulcer prevention (e.g., footwear, podiatry) and for ulcer treatment when required (e.g., consultation, hospitalisation, amputation). Incremental cost-effectiveness ratios were calculated for intervention versus usual care using probabilistic sensitivity analysis for willingness-to-pay/accept levels up to €100,000.

RESULTS

The intervention had a 45% probability of being cost-effective at a willingness-to-accept of €50,000 per QALY lost. This resulted from (non-significantly) lower foot care costs in the intervention group (€6067 vs. €7376; p = 0.45) because of (significantly) fewer participants with ulcer recurrence(s) in 18 months (36% vs. 47%; p = 0.045); however, QALYs were (non-significantly) lower in the intervention group (1.09 vs. 1.12; p = 0.35), especially in those without foot ulcer recurrence (1.09 vs. 1.17; p = 0.10).

CONCLUSIONS

At-home skin temperature monitoring for diabetes-related foot ulcer prevention compared with usual care is at best equally cost-effective. The intervention resulted in cost-savings due to preventing foot ulcer recurrence and related costs, but this came at the expense of QALY loss, potentially from self-monitoring burdens.

The Impact of Underlying Conditions on Quality-of-Life Measurement Among Patients with Chronic Wounds, as Measured by Utility Values: A Review with an Additional Study

Significance: Quality of life (QoL) is important to patients with chronic wounds and is rarely formally evaluated. Understanding what comorbidities most affect the individual versus their wounds could be a key metric. Recent Advances: The last 20 years have seen substantial advances in QoL instruments and conversion of patient data to a single value known as the health utilities index (HUI). We review these advances, along with wound-related QoL, and analyze real-world comorbidities challenging wound care. Critical Issues: To understand the impact of underlying comorbidities in a real-world patient population, we examined a convenience sample of 382 patients seen at a hospital-based outpatient wound center. This quality reporting study falls outside the regulations that govern human subject research. Comorbid conditions were used to calculate HUIs using a variety of literature-reported approaches, while Wound-Quality-of-Life (W-QoL) questionnaire data were collected from patients during their first visit. The mean number of conditions per patient was 8; 229 patients (59.9%) had utility values for comorbidities/conditions, which were worse/lower than their wounds' values. Sixty-three (16.5%) patients had depression and/or anxiety, 64 (16.8%) had morbid obesity, and 204 (53.4%) had gait and mobility disorders, all of which could have affected W-QoL scoring. The mean minimum utility value (0.5) was within 0.05 units of an average of 13 studies reporting health utilities from wound care populations using the EuroQol 5 Dimension instrument. Future Directions: The comorbidity associated with the lowest utility value is what might most influence the QoL of patients with chronic wounds. This finding needs further investigation.

Does Lower Extremity Nerve Decompression Surgery Improve Quality of Life?

BACKGROUND

Entrapment neuropathies are more prevalent in patients with diabetes than in healthy patients. The aim of this study was to assess the effects of lower extremity nerve decompression surgery on quality of life and clarify predictors of this surgical outcome and the incidence of surgical site problems.

METHODS

Patients who underwent lower extremity nerve decompression surgery between September of 2017 and March of 2019 were followed prospectively at the outpatient clinic of University Medical Center Utrecht. The common, superficial, and deep peroneal nerve and tibial nerve at the tarsal tunnel and soleal sling were decompressed if an entrapment was diagnosed. The primary study outcome was quality of life as measured by the Norfolk Quality of Life-Diabetic Neuropathy questionnaire. Secondary outcomes of interest were change in Michigan Neuropathy Screening Instrument score, predictors of the Norfolk score at follow-up, and the occurrence of complications.

RESULTS

Sixty patients underwent surgery (45 unilateral, 15 bilateral), with a median postoperative follow-up of 13.0 months (interquartile range, 7.3 to 18.0 months). Quality of life improved significantly in this period of observation [baseline median, 46.0 (34.0 to 62.0) versus follow-up median, 37.0 (20.0 to 60.0); p = 0.011], as did Michigan Neuropathy Screening Instrument scores [7.0 (5.0 to 9.0) versus 3.0 (0.0 to 6.5); p < 0.01]. Predictors of quality of life were a higher baseline quality of life score [β, 0.59 ( p = 0.001)], longer follow-up time [β, 2.34 ( p < 0.001)], and hypertension [β, 16.38 ( p = 0.03)]. A total of 26.7 percent of patients had surgical site problems, including wound infections (18.3 percent).

CONCLUSIONS

Lower extremity nerve decompression surgery significantly improves quality of life by reducing neuropathy symptoms in patients with lower extremity nerve compressions. Attention should be given to lowering the risk of wound complications.

CLINICAL QUESTION/LEVEL OF EVIDENCE

Therapeutic, III.